Daiken Biomedical Ratios and Metrics

Market cap in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 5, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Market Capitalization	17,942	10,860	-	-
Enterprise Value	12,898	9,874	-	-
Last Close Price	22.15	17.34	-	-
PE Ratio	50.70	101.90	-	-
PS Ratio	10.06	7.97	-	-
PB Ratio	3.35	8.31	-	-
P/TBV Ratio	3.36	8.33	-	-
P/FCF Ratio	60.79	215.06	-	-
P/OCF Ratio	60.67	209.86	-	-
EV/Sales Ratio	7.23	7.25	-	-
EV/EBITDA Ratio	46.18	64.48	-	-
EV/EBIT Ratio	47.27	66.31	-	-
EV/FCF Ratio	43.70	195.53	-	-
Debt / Equity Ratio	0.00	0.00	1.12	0.60
Debt / EBITDA Ratio	0.07	0.01	1.35	1.21
Debt / FCF Ratio	0.07	0.05	2.63	3.27
Net Debt / Equity Ratio	-0.94	-0.87	-0.04	-0.47
Net Debt / EBITDA Ratio	-18.06	-7.43	-0.05	-0.96
Net Debt / FCF Ratio	-17.09	-22.52	-0.10	-2.59
Asset Turnover	0.48	1.19	1.87	-
Inventory Turnover	1.78	1.99	1.71	-
Quick Ratio	17.91	5.36	0.80	1.23
Current Ratio	19.43	6.56	1.64	2.17
Return on Equity (ROE)	8.09%	13.71%	67.55%	-
Return on Assets (ROA)	4.63%	8.15%	20.01%	-
Return on Invested Capital (ROIC)	195.95%	55.95%	94.00%	77.31%
Return on Capital Employed (ROCE)	5.10%	11.40%	68.80%	38.90%
Earnings Yield	1.50%	0.98%	-	-
FCF Yield	1.65%	0.46%	-	-
Dividend Yield	1.83%	2.33%	-	-
Payout Ratio	217.98%	2.89%	87.59%	-
Buyback Yield / Dilution	-77.82%	-95.20%	-44.34%	-
Total Shareholder Return	-75.95%	-92.87%	-44.34%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.